retatrutide phase 3 triumph 🚨 JUST RELEASED TODAY!!!! NEW DATA Today, July 23, 2026, new Phase 3 retatrutide results were released, adding to what is already one of the most interesting obesity drug Retatrutide produces up to 30.3%

Pregnant or nursing mothers, children under the age of 18, and individuals with a known medical condition should consult a physician before using this or any dietary supplement

Its an active area of research, Hardaway said

Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, and Gribble FM

By talking openly with your healthcare providers, you can find the right tool to help you manage your weight and your health, she adds

Finally, similar to GLP-1 RAs, the medication should not be used in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [31, 43]

Provider evaluation determines eligibility on an individual basis - and that clinical gatekeeping is exactly how it should work with prescription medications